Agile And Differentiated, AlphaMab Riding High In China Biotech Boom
This article was originally published in PharmAsia News
AlphaMab is attracting attention as the Suzhou-based biotech has filed China's first PD-L1 antibody, giving it a lead over larger and multinational competitors. The venture’s winning strategy lies in staying ahead of the curve, CEO Xu Ting told PharmAsia News in an exclusive interview.
You may also be interested in...
A busy stretch of deal-making across Asia all includes transactions involving Innovent, Alector, Ono, Numab, Alphamab, 3DMed, Healios, Athersys, Laekna, Novartis, Asahi Kasei, SBI Biotech, Glenmark, Hindustan Unilever, Hanlim, Alteogen, Ildong, Evotec, AJU Pharm, Ribomec, Tyligand, Context
The latest development over the licensing arrangement for the anticancer drug may deal a further blow to BeiGene’s oncology commercial efforts in China.
China’s booming biotech sector shows no signs of slowing and is spurring many contract clinical and manufacturing service providers to double their bets in a market that remains largely untapped for innovative biologics. But whether the boom will turn to a bubble remains to be seen.